BiotechTube
Nasus Pharma

Nasus Pharma

NSRX
Rehovot, Israel· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

NSRX · Stock Price

USD 3.39-4.86 (-58.91%)
Market Cap: $39.6M

Historical price data

Overview

Nasus Pharma is a publicly traded Israeli biotech focused on developing intranasal formulations for emergency and acute care, with a mission to replace invasive injections. Its lead asset, FMXIN002 (intranasal epinephrine), has completed Phase I for anaphylaxis, while FMXIN007 (intranasal dexamethasone) targets immunotherapy-related adverse events. The company's strategy hinges on validating its proprietary nasal delivery platform to address significant unmet needs in allergy and oncology supportive care, aiming for improved usability, compliance, and accessibility. As an early-stage public entity with a ~$20M valuation, it faces the dual challenge of clinical execution and navigating a competitive landscape.

Allergy & ImmunologyOncology Supportive Care

Technology Platform

Proprietary intranasal drug delivery platform engineered for rapid systemic absorption of medications through the nasal mucosa, bypassing the GI tract and first-pass liver metabolism.

Opportunities

FMXIN002 addresses a multi-billion dollar anaphylaxis market dominated by needle-based auto-injectors, with a needle-free alternative that could significantly improve patient compliance and accessibility.
FMXIN007 targets a growing, high-need niche in oncology supportive care driven by the expansion of immunotherapy, offering a potential at-home intervention for severe side effects.

Risk Factors

The lead program faces significant clinical and regulatory risk, needing to prove rapid absorption comparable to intramuscular injection—a high technical bar.
As a micro-cap, pre-revenue company, Nasus faces substantial financial risk and likely dilution from future capital raises required to fund development.
It also enters a competitive landscape for intranasal epinephrine with at least one significantly more advanced competitor.

Competitive Landscape

In intranasal epinephrine, ARS Pharmaceuticals (neffy®) is the clear front-runner, having completed Phase 3 trials, setting both a validation precedent and a high regulatory benchmark. For FMXIN007 in immune-related adverse events, competition is less direct but the challenge is demonstrating that intranasal delivery can achieve systemic levels sufficient to treat severe inflammatory crises.

More companies in Israel →